As competition heats up in the race to find innovative lipid-management drugs that work on patients when statins do not, first-to-market positioning, efficacy and pricing are likely to be top differentiators.
Furthest along in so far the high-profile PCSK9 inhibitor class are Regeneron Pharmaceuticals Inc. and Sanofi with a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?